Article
Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Apr 2020
Yaeger Rona, Solit David B
Abstract excerpt
KRAS G12C inhibitors have shown promise in KRAS G12C-mutant lung cancer but intrinsic and acquired resistance are common. Cotreatment with inhibitors of the protein phosphatase SHP2 can abrogate the adaptive response of cancer cells to KRAS inhibitors resulting in greater suppression of MAPK signaling and enhanced tumor growth inhibition.See related article by Ryan et al., p. 1633.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.